INDV-1000 is a GABAB receptor positive allosteric modulator (PAM) which is under development for the treatment of substance-related disorders. Its route of administration is unspecified. The drug is under development by Indivior in partnership with Addex Therapeutics. As of April 2024, it is in the preclinical research stage of development. The chemical structure of INDV-1000 does not yet appear to have been disclosed. It is one of a limited number of known GABAB receptor PAMs as of 2024.
See also GABAB receptor § Positive allosteric modulators List of investigational substance-related disorder drugs
References